Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
Status:
Terminated
Trial end date:
2020-12-08
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of HM61713
in patients with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an
epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI).